Item 1A. RISK FACTORS
3K characters. Original on sec.gov ·
Item 1A. RISK FACTORS
There have been no material changes in the company's risk factors from those disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026.
| Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Issuer Purchases of Equity Securities
| Period | Total Number of Shares (or Units) Purchased (1) | Average Price Paid Per Share (or Unit) | Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs (1) | Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs (in millions) (1) | ||||||||||||||||||||||
| July 1 to July 31 | 1,135,664 | (2) | $ | 243.33 | 1,134,275 | $ | 1,228.4 | |||||||||||||||||||
| August 1 to August 31 | 515,523 | (3) | 268.71 | 515,471 | 1,089.8 | |||||||||||||||||||||
| September 1 to September 30 | 478,803 | (4) | 274.66 | 397,488 | 980.6 | |||||||||||||||||||||
| Total | 2,129,990 | (5) | 2,047,234 |
(1)CME Group maintains a share repurchase program under which CME Group is authorized to repurchase up to $3.0 billion of its outstanding Class A common stock, par value $0.01 per share (the common stock) as announced on December 5, 2024. The share repurchase program has no expiration date.
(2)Includes an aggregate of 1,389 shares of Class A common stock surrendered to satisfy employees' tax obligations upon the vesting of restricted stock.
(3)Includes an aggregate of 52 shares of Class A common stock surrendered to satisfy employee's tax obligations upon the vesting of restricted stock.
(4)Includes an aggregate of 81,315 shares of Class A common stock surrendered to satisfy employee's tax obligations upon the vesting of restricted stock.
(5)Shares purchased includes an aggregate of 82,756 shares of Class A common stock surrendered to satisfy employee tax obligations upon the vesting of restricted stock.
Previous: Item 4. CONTROLS AND PROCEDURES · Next: Item 5. OTHER INFORMATION